This study is testing a new drug called KK2269 for adults with advanced or metastatic solid tumors (cancers that have spread). It's the first time KK2269 is being given to people. The study has two parts. In Part 1, researchers will look at the safety of KK2269 by itself. In Part 2, they will study KK2269 combined with another cancer drug called Docetaxel in people with specific cancers like stomach (gastric), gastroesophageal junction (GEJ), or esophageal adenocarcinoma. The main goal is to see how safe KK2269 is, both alone and with Docetaxel, and to find the best dose. You may be able to join if you are 18 or older, have a measurable tumor, and a good general health status. The current recruitment status is unclear.

Study design

This is a multicenter, open-label (meaning you and your doctors will know what treatment you are receiving), non-randomized study. It is a dose-escalation study, meaning participants will receive increasing doses to find the safest and most effective amount. The planned enrollment is 101 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your safety will be monitored for about one year, from when you sign the consent form until the study is complete. Dose-limiting side effects will be checked for 21 days after your first dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.